A Multi-center, Open-label, Comparison and a Parallel Group Study (3 Groups) Phase 3 Clinical Trial for a Comparative Evaluation With the Existing Treatments, in Order to Verify the Long-term Efficacy and Safety of the First Cell Treatment Using Hearticellgram-AMI(Autologous Human Bone Marrow Derived Mesenchymal Stem Cells) in AMI Patients, and to Observe the Efficacy of the Second Cell Treatment.
Phase of Trial: Phase III
Latest Information Update: 22 Sep 2017
At a glance
- Drugs Mesenchymal stem cell therapy (Primary)
- Indications Myocardial infarction
- Focus Therapeutic Use
- Acronyms RELIEF
- Sponsors Pharmicell
- 18 Sep 2017 Planned primary completion date changed from 1 Dec 2018 to 31 Dec 2020.
- 01 Feb 2015 Planned primary completion date changed from 1 Nov 2014 to 1 Dec 2018 as reported by ClinicalTrials.gov record.
- 14 Nov 2013 Planned end date changed from 1 Jan 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov.